Shah Rajeev M.
SEC CIK 1619841 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | Dir | 5.83M | $8.76M | — | 1 | 2026-03-27 | 2026-03-27 |
| ABOS | Acumen Pharmaceuticals, Inc. | Dir, 10% | 19.10M | $30.00M | — | 3 | 2021-07-06 | 2026-03-16 |
| VOR | Vor Biopharma Inc. | Dir, 10% | 1.85M | — | $13.71M | 2 | 2022-12-09 | 2025-10-15 |
| SEPN | Septerna, Inc. | Dir, 10% | 1.13M | $75.06M | — | 2 | 2024-10-28 | 2024-10-28 |
| FULC | Fulcrum Therapeutics, Inc. | 10% | 3.11M | — | — | 1 | 2024-08-21 | 2024-08-21 |
| JBIO | Jade Biosciences, Inc. | Dir, 10% | 7.89M | $40.55M | — | 3 | 2021-07-02 | 2024-06-17 |
| TYRA | Tyra Biosciences, Inc. | Dir, 10% | 8.48M | — | — | 1 | 2024-02-06 | 2024-02-06 |
| HOWL | Werewolf Therapeutics, Inc. | Dir, 10% | 5.70M | $4.10M | — | 1 | 2023-01-06 | 2023-01-06 |
| ELVN | Enliven Therapeutics, Inc. | 10% | 3.25M | $452.4K | — | 2 | 2022-10-20 | 2022-12-08 |
| SPRY | ARS Pharmaceuticals, Inc. | Dir | 902.9K | — | — | 1 | 2022-11-08 | 2022-11-08 |
| ANTX | AN2 Therapeutics, Inc. | 10% | 3.77M | $16.7K | — | 2 | 2022-06-21 | 2022-08-03 |
| KALA | KALA BIO, Inc. | 10% | 9.48M | — | $1.49M | 1 | 2022-05-23 | 2022-05-23 |
| NKTX | Nkarta, Inc. | Dir, 10% | 7.81M | $33.00M | — | 1 | 2022-04-26 | 2022-04-26 |
| CTKB | Cytek Biosciences, Inc. | Dir | 12.20M | $29.83M | — | 4 | 2022-02-17 | 2022-03-09 |
Most active insiders at MLYS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Catalys Pacific Fund, LP | 10% | — | $43.35M |
| 2 | Congleton Jon | CEO, Dir | — | $14.91M |
| 3 | Rodman David Malcom | Chief Medical Off | — | $14.41M |
| 4 | Shah Rajeev M. | Dir | $8.76M | — |
| 5 | Levy Adam Scott | CFO, Sec | — | $6.16M |
| 6 | Warren Eric | Chief Commercial Off | — | $3.30M |
| 7 | Slingsby Brian Taylor | Dir, 10% | — | $3.01M |
| 8 | Gold Alexander M | Dir | — | $1.58M |
| 9 | Karydas Daphne | Dir | — | $925.6K |
| 10 | DiRocco Derek | Dir | — | — |
Transactions 25
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2026-03-31 | 2026-03-27+ | MLYS | Mineralys Therapeutics, Inc. | Shah Rajeev M. | Dir | P - Purchase | $23.75 | +369.0K | 5.83M | +7% | +$8.76M |
| I | 2026-03-18 | 2026-03-16 | ABOS | Acumen Pharmaceuticals, Inc. | Shah Rajeev M. | Dir, 10% | A - Grant | $3.30 | +6.06M | 19.10M | +46% | +$20.00M |
| MI | 2025-10-17 | 2025-10-15+ | VOR | Vor Biopharma Inc. | Shah Rajeev M. | Dir, 10% | S - Sale | $29.54 | -464.0K | 1.85M | -20% | -$13.71M |
| DMI | 2024-10-30 | 2024-10-28 | SEPN | Septerna, Inc. | Shah Rajeev M. | Dir, 10% | C - Cnv Deriv | — | +2.83M | 1.13M | New | — |
| DMI | 2024-10-30 | 2024-10-28 | SEPN | Septerna, Inc. | Shah Rajeev M. | Dir, 10% | P - Purchase | $18.00 | +4.17M | 1.47M | New | +$75.06M |
| DI | 2024-08-23 | 2024-08-21 | FULC | Fulcrum Therapeutics, Inc. | Shah Rajeev M. | 10% | J - Other | — | -8.50M | 3.11M | -73% | — |
| I | 2024-06-20 | 2024-06-17 | JBIO | Jade Biosciences, Inc. | Shah Rajeev M. | Dir, 10% | P - Purchase | $1.67 | +928.1K | 7.89M | +13% | +$1.55M |
| DI | 2024-02-08 | 2024-02-06 | TYRA | Tyra Biosciences, Inc. | Shah Rajeev M. | Dir, 10% | A - Grant | $13.01 | +3.18M | 8.48M | +60% | +$41.37M |
| I | 2023-01-10 | 2023-01-06 | HOWL | Werewolf Therapeutics, Inc. | Shah Rajeev M. | Dir, 10% | P - Purchase | $2.21 | +1.85M | 5.70M | +48% | +$4.10M |
| MI | 2022-12-12 | 2022-12-08+ | ELVN | Enliven Therapeutics, Inc. | Shah Rajeev M. | 10% | P - Purchase | $3.87 | +29.9K | 3.25M | +0.9% | +$115.6K |
| I | 2022-12-09 | 2022-12-09 | VOR | Vor Biopharma Inc. | Shah Rajeev M. | Dir, 10% | A - Grant | $4.30 | +11.63M | 20.92M | +125% | +$50.00M |
| MI | 2022-11-10 | 2022-11-08 | SPRY | ARS Pharmaceuticals, Inc. | Shah Rajeev M. | Dir | A - Grant | — | +3.01M | 902.9K | New | — |
| MI | 2022-10-24 | 2022-10-20+ | ELVN | Enliven Therapeutics, Inc. | Shah Rajeev M. | 10% | P - Purchase | $3.92 | +85.9K | 3.15M | +3% | +$336.8K |
| MI | 2022-08-05 | 2022-08-03+ | ANTX | AN2 Therapeutics, Inc. | Shah Rajeev M. | 10% | P - Purchase | $7.51 | +1,909 | 3.77M | +0.1% | +$14.3K |
| I | 2022-06-23 | 2022-06-21 | ANTX | AN2 Therapeutics, Inc. | Shah Rajeev M. | 10% | P - Purchase | $7.99 | +302 | 3.75M | +0.0% | +$2,413 |
| MI | 2022-05-25 | 2022-05-23+ | KALA | KALA BIO, Inc. | Shah Rajeev M. | 10% | S - Sale | $0.5262 | -2.83M | 9.48M | -23% | -$1.49M |
| I | 2022-04-28 | 2022-04-26 | NKTX | Nkarta, Inc. | Shah Rajeev M. | Dir, 10% | P - Purchase | $15.00 | +2.20M | 7.81M | +39% | +$33.00M |
| MI | 2022-03-11 | 2022-03-09+ | CTKB | Cytek Biosciences, Inc. | Shah Rajeev M. | Dir | P - Purchase | $12.86 | +634.6K | 12.20M | +5% | +$8.16M |
| MI | 2022-03-08 | 2022-03-04+ | CTKB | Cytek Biosciences, Inc. | Shah Rajeev M. | Dir | P - Purchase | $12.74 | +647.3K | 11.92M | +6% | +$8.25M |
| MI | 2022-03-02 | 2022-02-28+ | CTKB | Cytek Biosciences, Inc. | Shah Rajeev M. | Dir | P - Purchase | $12.95 | +441.9K | 11.08M | +4% | +$5.72M |
| MI | 2022-02-22 | 2022-02-17+ | CTKB | Cytek Biosciences, Inc. | Shah Rajeev M. | Dir | P - Purchase | $14.06 | +547.4K | 10.27M | +6% | +$7.70M |
| DMI | 2021-07-08 | 2021-07-06 | ABOS | Acumen Pharmaceuticals, Inc. | Shah Rajeev M. | Dir, 10% | P - Purchase | $16.00 | +1.88M | 7.88M | +31% | +$30.00M |
| DMI | 2021-07-08 | 2021-07-06 | ABOS | Acumen Pharmaceuticals, Inc. | Shah Rajeev M. | Dir, 10% | C - Cnv Deriv | — | +7.90M | 588.9K | New | — |
| DMI | 2021-07-06 | 2021-07-02 | JBIO | Jade Biosciences, Inc. | Shah Rajeev M. | Dir, 10% | C - Cnv Deriv | — | +5.24M | 4.18M | New | — |
| DI | 2021-07-06 | 2021-07-02 | JBIO | Jade Biosciences, Inc. | Shah Rajeev M. | Dir, 10% | P - Purchase | $14.00 | +2.79M | 6.97M | +67% | +$39.00M |
Purchase Sale Sale after option exercise All abbreviations